Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout
Currently, only two drugs for reducing uric acid (UA), allopurinol and febuxostat, are registered in the Russian Federation, but their use does not allow to achieve the target level of UA in all cases. According to the results of numerous randomized trials, hyperuricemia and gout are associated with...
Main Authors: | T. S. Panevin, M. S. Eliseev, M. V. Shestakova, E. L. Nasonov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
"Consilium Medicum" Publishing house
2020-06-01
|
Series: | Терапевтический архив |
Subjects: | |
Online Access: | https://ter-arkhiv.ru/0040-3660/article/viewFile/34592/pdf |
Similar Items
-
Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives
by: Mathew John, et al.
Published: (2016-01-01) -
NEW OPPORTUNITIES FOR CORRECTION OF HYPERURICEMIA IN GOUT
by: Svetlana Evgenyevna Myasoedova, et al.
Published: (2009-12-01) -
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
by: Santos Cavaiola T, et al.
Published: (2018-04-01) -
Research status of genes related to primary gout and hyperuricemia
by: Bai Xue, et al.
Published: (2019-08-01) -
The Role of ABCG2 in the Pathogenesis of Primary Hyperuricemia and Gout—An Update
by: Robert Eckenstaler, et al.
Published: (2021-06-01)